Sanofi SA
SNY54.950USD
+1.230+2.29%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
137.77BMarket Cap
22.76P/E TTM
More Details of Sanofi SA Company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
Company codeSNY
Company nameSanofi SA
IPO dateJul 01, 2002
Founded at1994
CEOMr. Paul Hudson, Ph.D.
Number of employees84587
Security typeDepository Receipt
Fiscal year-endJul 01
Address46 Avenue de la Grande Armee
CityPARIS
Stock exchangeNASDAQ Global Select Consolidated
CountryFrance
Postal code75017
Phone33153774000
Websitehttps://www.sanofi.com/
Company codeSNY
IPO dateJul 01, 2002
Founded at1994
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
By RegionUSD
Name
Revenue
Proportion
United States
21.62B
48.65%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
13.05B
29.38%
Europe excl. France
7.80B
17.56%
France
1.96B
4.42%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
Shareholder
Update time: Fri, Apr 18
Update time: Fri, Apr 18
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Dodge & Cox
2.98%
Fisher Investments
0.50%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.43%
Capital World Investors
0.32%
Other
95.32%
Shareholder Statistics
Shareholder
Proportion
Dodge & Cox
2.98%
Fisher Investments
0.50%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.43%
Capital World Investors
0.32%
Other
95.32%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
5.55%
Investment Advisor
4.17%
Research Firm
0.77%
Hedge Fund
0.29%
Bank and Trust
0.07%
Pension Fund
0.02%
Family Office
0.01%
Other
89.12%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1247
278.50M
11.02%
-14.39M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
2022Q4
1167
264.16M
10.47%
-6.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
75.22M
2.98%
-1.08M
-1.41%
Dec 31, 2024
Fisher Investments
12.51M
0.5%
-848.08K
-6.35%
Dec 31, 2024
Invesco Advisers, Inc.
11.37M
0.45%
+303.99K
+2.75%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.84M
0.43%
+5.09M
+88.50%
Dec 31, 2024
Managed Account Advisors LLC
7.74M
0.31%
-611.48K
-7.32%
Dec 31, 2024
Barrow Hanley Global Investors
7.70M
0.3%
-140.54K
-1.79%
Dec 31, 2024
Boston Partners
5.40M
0.21%
+2.50M
+86.38%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.95M
0.2%
-3.65M
-42.49%
Dec 31, 2024
Wellington Management Company, LLP
4.48M
0.18%
-166.02K
-3.57%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
VanEck Pharmaceutical ETF
5.04%
Invesco International Dividend Achievers ETF
3.48%
Putnam Focused Large Cap Value ETF
2.86%
Pacer Global Cash Cows Dividend ETF
2.16%
Brandes US Value ETF
2.03%
Altrius Global Dividend ETF
1.99%
Pacer Trendpilot European Index ETF
1.95%
ProShares Ultra Nasdaq Biotechnology
1.59%
Invesco Nasdaq Biotechnology ETF
1.57%
Simplify Health Care ETF
1.57%
View more
VanEck Pharmaceutical ETF
Proportion5.04%
Invesco International Dividend Achievers ETF
Proportion3.48%
Putnam Focused Large Cap Value ETF
Proportion2.86%
Pacer Global Cash Cows Dividend ETF
Proportion2.16%
Brandes US Value ETF
Proportion2.03%
Altrius Global Dividend ETF
Proportion1.99%
Pacer Trendpilot European Index ETF
Proportion1.95%
ProShares Ultra Nasdaq Biotechnology
Proportion1.59%
Invesco Nasdaq Biotechnology ETF
Proportion1.57%
Simplify Health Care ETF
Proportion1.57%
Dividend
A total of
23.51B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data